THE METABOLIC SYNDROME WITH INSULIN RESISTANCE is a well-established major risk factor for cardiovascular disease (18, 35, 37, 38) . A part of this increased cardiovascular risk is thought to be due to endothelial lipotoxicity, which is caused by elevated levels of circulating nonesterified free fatty acids (NEFAs), which are closely associated with insulin resistance (25, 31, 45) . Lipotoxicity has been implicated in the pathogenesis of endothelial dysfunction with initiation of vascular inflammation, progression of atherosclerotic lesions, and, finally, atherosclerotic complications like atherothrombosis, stroke, and myocardial infarction. Endothelial dysfunction, determined by impaired endothelium-dependent vasodilatation, is considered to be an early functional stage of atherosclerosis accompanied by vascular inflammation that precedes morphological changes of the vessel wall (4) and is predictive for cardiovascular events (20, 41, 49) . Elevated plasma NEFA levels are positively correlated with endothelial dysfunction (42) . The acute effect of NEFAs on endothelial function in vivo has been studied by Steinberg et al. (48) , who observed significant endothelial dysfunction in humans after elevation of circulating NEFA levels by lipid infusion. One widely proposed mechanism could be the induction of inflammatory cytokines in arterial endothelial cells (44) . Distinct effects of saturated and unsaturated NEFAs have been observed, and apparently, the composition of free fatty acids is more relevant to endothelial function and vascular inflammation than the total amount of NEFAs (44, 46) . The most abundant saturated fatty acid in human plasma, palmitate, has a high potency for the induction of inflammatory cytokines in endothelial cells, and the palmitate content of circulating NEFAs correlates with serum levels of IL-6 (44) . These results provide a potential mechanism for how saturated NEFAs can trigger vascular inflammation and contribute to endothelial dysfunction in early stages of atherosclerosis. The role of NEFAs in the development of cardiovascular complications in later stages of atherosclerosis has also been attributed to the induction of endothelial cell apoptosis (13, 15, 45) . Saturated NEFAs can induce endothelial cell apoptosis (45) , leading to denudation of the endothelial layer and subsequent vessel thrombosis (15) . This may be a critical mechanism for plaque erosion and atherothrombosis (13) and a cause of myocardial infarction or stroke. Elevated levels of NEFAs have been demonstrated to influence mortality in patients with clinically overt atherosclerosis (34) . Both lipotoxic effects, inflammation and apoptosis, are induced by saturated NEFAs and can be reversed by addition of unsaturated NEFAs (30, 44, 45) . StearoylCoA desaturase is the limiting enzyme that converts saturated fatty acids to monounsaturated fatty acids, thus providing an endogenous source of unsaturated fatty acids. Therefore, enhancing the activity of human stearoyl-CoA desaturase-1 (hSCD-1) could be a strategy to prevent the toxic effects of saturated NEFAs.
A new group of substances activating the liver X receptor (LXR) has proven to possess antiatherogenic properties in atherosclerosis-prone mouse models apoE Ϫ/Ϫ and LDL receptor Ϫ/Ϫ (27, 50) . The effect has been attributed mainly to an influence on reverse cholesterol transport and inhibition of inflammation. Through induction of the monocytic ATP-binding cassette transporter A1, excess cholesterol is transferred from atherosclerotic plaques to HDL and raises plasma HDL cholesterol levels. LXR activators have been shown to inhibit NF-B-dependent induction of inflammatory gene expression in macrophages through not fully understood mechanisms (57) .
However, in addition to genes linked to the reverse cholesterol transport, LXR agonists upregulate hepatic genes involved in fatty acid and triglyceride synthesis; among these is hSCD-1 (9, 26) . In this study, we test the hypothesis that the LXR activator TO-901317 induces endothelial hSCD-1 expression, thereby providing a strategy to prevent lipotoxic effects of palmitate on endothelial cell viability and inflammation.
EXPERIMENTAL PROCEDURES
Cell culture. Human arterial endothelial cells (HAECs) were isolated from adult human iliac arteries of transplant donors by mechanically removing the endothelial layer as previously described (3) and were cultured in endothelial growth medium-2 (Clonetics, Walkersville, MD) containing 2% FCS on culture flasks (Greiner, Frickenhausen, Germany) coated with 2% gelatin. Immunocytochemical staining showing the presence of the von Willebrand factor (Boehringer Mannheim) and absence of ␣-smooth muscle actin (Progen, Heidelberg, Germany) was performed to prove endothelial cell origin. Cells were kept in this medium during all experiments and were not serum starved. Only cells from passages 2 through 8 were used for experiments. Human coronary artery smooth muscle cells (CASMCs) and the corresponding cell culture media were obtained from Clonetics/BioWhittaker (Verviers, Belgium). The cells, derived from healthy Caucasian donors, were cultured according to the supplier's instructions. Human myotubes were differentiated from primary skeletal muscle cells from healthy, normal-weight Caucasians (19 females and 21 males, aged 26 Ϯ 4.8 yr, body mass index 23.5 Ϯ 3.45 kg/m 2 ). The skeletal muscle cells were obtained by percutaneous needle biopsies performed on the lateral portion of the quadriceps femoris (vastus lateralis) muscle, as described recently (53) . HepG2 hepatoma cells, baby hamster kidney (BHK) cells, and human embryonic kidney (HEK)-293 cells were cultured in DMEM (BioWhittaker) containing nonessential amino acids supplemented with 2 mmol/l glutamine, 1 mmol/l pyruvate, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 10% FCS. Cells were incubated with the indicated concentrations of NEFAs.
Preparation of NEFAs. NEFAs (Sigma-Aldrich, Taufkirchen, Germany) cis-10,trans-12-conjugated linoleic acid (10/12 CLA) and cis-9,trans-11-conjugated linoleic acid (9/11 CLA) (Matreya, Pleasant Gap, PA) were bound to BSA, as described previously (53) . In brief, NEFAs (200 mM in ethanol) were diluted to a final concentration of 6 mM in a 10% BSA solution (Fraction V, fatty acid free, endotoxin tested; Sigma-Aldrich). Stearate was prepared as a 2.5-mM BSA-coupled solution. This mixture was gently agitated at 37°C under nitrogen overnight. Control medium containing ethanol and BSA was prepared accordingly. At the NEFA concentration used, BSA reached a concentration of 1% (wt/vol) in the medium. TO-901317 was obtained from Sigma-Aldrich and added to the cell culture medium as a 10-mM solution in DMSO. DMSO was added to control experiments in equal amounts.
Plasmid construction. A hemagglutinin (HA)-tagged hSCD-1 expression plasmid was constructed to test antibody specificity. The complete hSCD-1 open reading frame was amplified from human cDNA by PCR introducing a carboxy-terminal in-frame HA epitope tag using previously published primers (51) . The resulting fragment was inserted into the BamHI/XhoI sites of the pcDNA3(ϩ) vector , and HepG2 hepatoma cells (E) is shown. Cells were incubated with palmitate 0.5 mM for 20 h and hSCD-1 mRNA content determined by RT-PCR. No significant induction is observed in HAECs (n ϭ 7, P ϭ 0.58). Palmitate induces hSCD-1 expression in myotubes (n ϭ 40, P Ͻ 0.00001), HepG2 cells (n ϭ 7, P Ͻ 0.001), and CASMCs (n ϭ 7, P ϭ 0.0003). ***P Ͻ 0.001; ****P Ͻ 0.00001.
(Invitrogen, Karlsruhe, Germany); 0.2 g of the plasmid DNA was transfected into 4 ϫ 10 5 BHK cells in six-well dishes using Lipofectamin 2000 (Invitrogen, Karlsruhe, Germany) according to the manufacturer's instructions and harvested after 48 h. HEK-293 cells plated at 6 ϫ 10 4 cells/well of a 12-well plate were transfected with pcDNA3(ϩ) or the hSCD-1 expression vector using the Ca3(PO4)2-DNA coprecipitation method and exposed to palmitate/BSA after 24 h for 36 h (54).
Small interfering RNA. Small interfering RNA (siRNA) oligonucleotides targeting hSCD-1 were designed, synthesized, and annealed at Dharmacon Research (Lafayette, CO) as an ON TARGET plus SMART pool. An unrelated siRNA targeting firefly luciferase was used as control in all experiments. Transfection was performed with Lipofectamin (Invitrogen, Karsruhe, Germany) with 200 nM siRNA according to the instructions of the manufacturer. Briefly, 2 ϫ 10 5 HEK-293 cells/well were seeded in 12-well plates and transfected and treated; 24 h later, cells were stimulated as with TO-901317 for 20 h prior to exposure to palmitate-BSA for 36 h. Lactate dehydrogenase (LDH) release into the medium was measured to determine cytotoxicity.
Western blotting. Cells were lysed with 100 l of lysis buffer/sixwell dish (50 mM Tris, pH 7.6, 150 mM NaCl, 1% Triton X-100, containing protease and phosphatase inhibitors). Cytosolic extracts of endothelial cells were separated by sodium dodecyl sulfate polyacrylamide (10%) gel electrophoresis (55) . Proteins were transferred to a nitrocellulose membrane by semidry electroblotting, and immunodetection was performed using a mouse monoclonal antibody against ␣-HA (Babco, Richmond, CA), full-length recombinant hSCD-1 (ab19862; Abcam, Cambridge, UK), and glutamine:fructose-6-phosphate amidotransferase (GFAT) (56) .
RT-PCR. RNA isolation was performed using RNeasy silica gel columns (Qiagen, Hilden, Germany). Total RNA treated with RNasefree DNase I was transcribed into cDNA using Avian myoblastosis virus reverse transcriptase and the first-strand cDNA kit from Roche Diagnostics. Quantitative PCR was performed with SYBR Green I dye on a LightCycler 2.0 according to the instructions of the manufacturer (Roche Diagnostics). The primers were obtained from Invitrogen (Karlsruhe, Germany). Measurements were performed in duplicate.
Conditions for RT-PCR quantification of mRNAs were as follows: hSCD-1: 5Ј-TGCAGGACGATATCTCTAGC-3Ј, 5Ј-ACGATGAGCTC-CTGCTGTTA-3Ј, annealing at 58°C, 45 cycles, 3 mmol/l MgCl 2; IL-8: 5Ј-AAGAAACCACCGGAAGGAAC-3Ј, 5Ј-ACTTCTCCA-CAACCCTCTGC-3Ј, annealing at 68°C, 45 cycles, 3 mmol/l MgCl 2; IL-6: 5Ј-CCAGCTATGAACTCCTTCTC-3Ј, 5Ј-GCTTGTTCCTCA-CATCTCTC-3Ј, annealing at 63°C, 45 cycles, 3 mmol/l MgCl 2; GAPDH: 5Ј-GGTCTCTCTCTTCCTCTTGTGC-3Ј, 5Ј-ACGACAC-CAACTTCTCCACC-3Ј, annealing at 67°C, 45 cycles, 4 mmol/l MgCl 2; ␤-actin: 5Ј-GAGCAAGAGAGGCATCCTCA-3Ј, 5Ј-AGC-CTGGATAGCAACGTACA-3Ј, annealing at 67°C, 40 cycles, 5 mmol/l MgCl 2. LXR␣ and LXR␣ RT-PCR was performed in using a QuantiTect SYBR Green PCR kit and Quantitect Primer Assays (Hs_NR1H2_1_SG and Hs_NR1H3_1_SG) according to the manufacturer's instructions (Qiagen).
Cell cycle analysis. Confluent HAECs were treated as indicated. Detached cells were harvested from the supernatant by centrifugation and added to the adherent cells harvested by trypsinization. Cells were washed with PBS, fixed in 70% ice-cold ethanol, centrifuged, and washed again with PBS. After being stained with propidium iodide (50 g/ml) diluted in PBS containing ribonuclease A (100 g/ml), cells were subjected to flow cytometric analysis of DNA content using a Becton Dickinson (Heidelberg, Germany) FACScalibur cytometer. Percentages of cells in the different cell cycle phases were calculated by CellQuest software (Becton Dickinson).
Determination of cytotoxicity. After a preincubation with TO-901317 or DMSO, confluent cells were incubated with 0.6 mmol/l The cytosolic glutamine:fructose-6-phosphate amidotransferase (GFAT) protein expression was used as a loading control. B: after 24 h, the cells were exposed to 0.6 mM palmitate or BSA for 36 h, and cytotoxicity was determined by lactate dehydrogenase (LDH) release into the medium. Triton X-100-lysed cells are set as 100% cytotoxicity. Palmitate is cytotoxic in control transfected cells (19%, P Ͻ 0.01). hSCD-1 overexpression significantly reduces the palmitate-induced cytotoxicity (5%, P Ͻ 0.05). *P Ͻ 0.05; **P Ͻ 0.01. palmitate or BSA for 36 h. Release of the cytoplasmic enzyme LDH, indicating cytotoxicity, was measured using the Clinical Chemistry Analyzer Advia 1650 system (Bayer HealthCare, Fernwald, Germany). Background release from untreated cells was subtracted. Maximum release was measured after the addition of 1% Triton X-100 to control treated cells and set as 100% (12) .
Cellular fatty acid composition. HAECs were harvested in PBS containing 1% Triton X-100 and subjected to direct transesterification (29, 47) . The fatty acid methyl esters were quantified with cis- 13, 16, 19 -docosatrienoic acid as the internal standard using gas chromatography with a flame ionization detector (HP 5890; Hewlett-Packard, Waldbronn, Germany) on a 60 m ϫ 0.25 mm ϫ 0.2-m fused silica column (Rtx 2330; Rystek). Helium was used as carrier gas at a column head pressure of 16 psi. Total triglyceride content was determined enzymatically with the Clinical Chemistry Analyzer Advia 1650 system (Bayer HealthCare, Fernwald, Germany).
Oil Red O staining. HAECs were fixed in 10% formaldehyde after various treatments and stained with 0.5% Oil Red O (Sigma Chemical, St. Louis, MO) for 2 h, as described previously (6) . Representative photomicrographs are shown for each treatment condition.
Statistical analysis. Data were analyzed by Student's t-test. P Ͻ 0.05 was considered statistically significant. Data are given as means Ϯ SE.
RESULTS

SCD-1 protein is expressed in HAECs.
hSCD-1 is a lipogenic enzyme previously shown to be expressed in tissues involved in fatty acid metabolism like liver, adipose tissue, skeletal muscle, and sebaceous glands (10, 23, 32, 40, 58, 59) . In preliminary studies we observed significant mRNA expression of hSCD-1 in human vascular endothelial cells and smooth muscle cells. To study the protein expression of hSCD-1, the specificity of three commercially available antibodies against hSCD-1 was evaluated in BHK cells overexpressing recombinant human HA-tagged hSCD-1 (Fig. 1A) . The HA tag was used to identify overexpressed hSCD-1 protein. No hSCD-1 signal could be detected in untransfected BHK cells. Only one antibody (Abcam mouse monoclonal anti-human SCD-1) recognized the recombinant as well as endogenous hSCD-1 in the untransfected hepatoma cell line HepG2 in primary human myotubes and in human arterial endothelial cells, whereas the other commercial antibodies (rabbit polyclonal anti-human SCD-1 and Abcam rabbit polyclonal anti-human SCD-1; Alpha Diagnostic) did not detect hSCD-1 in our system (data not shown). Separated on a 10% polyacrylamide gel, hSCD-1 appeared as a double band at 37 and 35 kDa, probably due to partial proteolysis at the NH 2 terminus, as described previously (22) . The results indicate that hSCD-1 protein is expressed in HAEC.
The saturated fatty acid palmitate does not induce hSCD-1 mRNA expression in HAECs. The most abundant saturated NEFA in human plasma, palmitate, as a substrate of SCD-1 is known to induce SCD-1 expression in rat L6-GLUT4-myc myoblasts (51) . We studied whether palmitate can induce hSCD-1 expression in human cells. Using previously established experimental conditions (43, 44) , palmitate (0.5 mM for 20 h) significantly induced expression of hSCD-1 mRNA in primary human myotubes (2.03 Ϯ 0.16, P Ͻ 0.00001), primary human CASMCs (2.24 Ϯ 0.22, P Ͻ 0.001), and HepG2 hepatoma cells (1.72 Ϯ 0.13, P Ͻ 0.001) (Fig. 1, C-E) . In HAECs, however, no increase in hSCD-1 expression was detectable (Fig. 1B) . Accordingly, human coronary artery endothelial cells showed no significant increase in hSCD-1 mRNA (data not shown). Noteworthy is that primary human arterial endothelial cells are especially susceptible to saturated NEFA-induced lipoapoptosis compared with other cell types (45) . This led us to the hypothesis that the high degree of lipoapoptosis observed in endothelial cells might be due to less pronounced hSCD-1 levels under saturated NEFA exposure.
Overexpression hSCD-1 reduces palmitate-induced cytotoxicity. To investigate the effect of SCD-1 on palmitate-induced cytotoxicity, we first used a transient overexpression system in HEK-293 cells (Fig. 2A) . Cytotoxicity was determined as LDH LXR␣ and LXR␤ are expressed in HAECs. To establish a pharmacological model with increased hSCD-1 expression in HAECs, we treated cells with the LXR-activating compound TO-901317 for 20 h. Activators of LXR, apart from other effects, have been shown to induce SCD-1 expression in several tissues [e.g., in liver, skeletal muscle, kidney, and macrophages (9, 11, 52, 59) ]. First, we investigated whether the LXR is expressed in HAECs. Two receptor isoforms, LXR␣ and LXR␤, occurring with tissue-specific distribution have been described (57) . In a quantitative RT-RCR, we detected a strong mRNA expression of both isoforms LXR␣ and LXR␤ in HAECs (Fig. 3) . The predominant form in HAECs was LXR␣ with expression levels even higher than in HepG2 cells and primary human hepatocytes. In primary human myotubes, LXR␤ was the predominant isoform.
The LXR activator TO-901317 induces hSCD-1 expression in HAECs. Next, we studied the effect of LXR activation on endothelial hSCD-1 expression. HAECs were treated with TO-901317 for 20 h, and the expression of hSCD-1 mRNA was measured by quantitative RT-RCR. Treatment with 10 M TO-901317 increased the hSCD-1 mRNA in HAECs 3.0-fold (Fig. 4A) . Treatment with TO-901317 at concentrations of 0.01-10 M for 20 h increased hSCD-1 protein expression in a dose-dependent manner (Fig. 4, B and C) . For further studies we used 10 M to achieve a maximal LXR activation, as published previously (24) . These data indicate that LXR activators stimulate hSCD-1 mRNA and protein expression in human endothelial cells.
The LXR activator TO-901317 increases hSCD-1 activity in HAECs. To evaluate whether TO-901317 treatment-induced increase in hSCD-1 expression leads to enhanced desaturation of palmitate and stearate, the composition of cellular fatty acids was analyzed. HAECs were also exposed to palmitate for 5 h to observe the effect under conditions of substrate excess (Table 1) . Under basal conditions, exposure to TO-901317 led to a significant increase of the C16:1 content and the SCD-1 activity index, estimated from C16:1/C16:0 ratio. When exposed to palmitate for 5 h, the SCD-1 activity index for both C16:1/C16:0 and C18:1/C18:0 was elevated by TO-901317. These data indicate that increased SCD-1 mRNA and protein levels by treatment with TO-901317 result in increased enzyme activity, estimated from product/precursor ratios in HAECs. Therefore, treatment with TO-901317 is useful to study effects of pharmacological induction of hSCD-1 in HAECs.
The LXR activator TO-901317 reduces palmitate-induced cytotoxicity and apoptosis in HAECs. We hypothesize that induction of hSCD-1 expression and activity by TO-901317 prior to exposure to palmitate can reduce lipotoxicity in HAECs by desaturating and thereby detoxifying palmitate. Since preliminary experiments showed that cytotoxicity and apoptosis are induced after treatment with 0.6 mM palmitate for 36 h, this experimental condition was used. Exposure to palmitate caused 41 Ϯ 4% cytotoxicity in HAECs, as determined by an LDH release cytotoxicity assay (P Ͻ 0.00001; data not shown). Preincubation of HAECs with the LXR activator TO-901317 significantly reduced the palmitate-induced cytotoxicity by 27% (Fig. 5A) . However, induction of hSCD-1 expression is only one of many effects of LXR activators (9, 26) . To prove the hypothesis that this effect of TO-901317 is due to increased hSCD-1 expression and enzymatic activity, we first used a pharmacological approach in HAECs (7, 8) . We applied 10/12 CLA, an inhibitor of hSCD-1 activity (8, 33) , and the chemically related but inactive analog 9/11 CLA as control substances (Fig. 5A) . Inhibition of hSCD-1 by 10 M 10/12 CLA reversed the protective effect of TO-901317 against lipotoxicity. The chemically related but inactive 9/11 CLA (7, 8, 33) had no effect on TO-901317-induced protection from lipotoxicity. Both 10/12 CLA and 9/11 CLA alone had no effect on cell viability under these conditions (data not shown).
Next, we investigated the SCD-1 activity indexes upon treatment with TO-901317 and in addition to 10/12 CLA and 9/11 CLA (Fig. 5B) . The cells were treated with TO-901317 for 20 h, followed by palmitate 0.5 mM for 5 h. Ten micromolars CLA was added 30 min prior to the treatments. TO-901317 significantly increased SCD-1 activity indexes. This increase was inhibited to control levels by the SCD-1 inhibitor 10/12 CLA. The inactive control substance 9/11 CLA did not reduce TO-901317-stimulated SCD-1 activity indexes. Activity indexes with TO-901317 plus 9/11 CLA remained significantly higher than control or TO-901317 plus 10/12 CLA-treated cells (Fig. 5B) . Incubation with 10 M 10/12 CLA for 20 h did not significantly influence hSCD-1 mRNA expression in HAECs (93 Ϯ 20% of control, P ϭ 0.72, n ϭ 6, normalized to GAPDH). These data indicate that 10 M 10/12 CLA inhibits hSCD-1 activity in HAECs under the used experimental conditions.
To confirm that TO-901317 not only reduces palmitateinduced cytotoxicity but also prevents the initiation of apoptosis in HAECs, we measured the proportion of cells with a subG1 DNA content in a cell cycle assay. Palmitate induced apoptosis in HAECs (Fig. 5C ). The apoptosis rate was significantly reduced by preincubation with the LXR activator TO-901317 (66 Ϯ 7%, P ϭ 0.002; Fig. 5D ). Corresponding to the results of the cytotoxicity assays, the protective effects of TO-901317 were reversed by the hSCD-1 inhibitor 10/12 CLA (100 Ϯ 14%). Thus, the induction of hSCD-1 is necessary for the protective effects of TO-901317 against lipoapoptosis. TO-901317 . To further confirm relevance of hSCD-1 for the protective effects of TO-901317 against lipotoxicity on a molecular level, we reduced hSCD-1 protein expression by siRNA knockdown in HEK-293 cells (Fig. 6A) . In control transfected HEK-293 cells, TO-901317 reduced palmitate-induced cytotoxicity by 58%. This effect was almost abolished by Fig. 5 . A: palmitate induces cytotoxicity in HAECs. Cytotoxicity was determined by LDH release into the culture medium and is set as 100%. This effect is ameliorated by a preincubation with the LXR activator TO-901317 by 27%. Protection from palmitate-induced cytotoxicity by TO-901317 was prevented by 10 M of the SCD-1 inhibitor cis-10,trans-12-conjugated linoleic acid (10/12 CLA) but not the inactive control substance cis-9,trans-11-conjugated linoleic acid (9/11 CLA). The relative palmitate-induced cytotoxicity for TO-901317 alone and in addition to 10/12 CLA and 9/11 CLA vs. DMSO alone and in addition to 10/12 CLA and 9/11 CLA is displayed. HAECs were incubated with 10 M TO-901317 prior to 0.6 mM palmitate for 36 h. hSCD-1 activity is inhibited by 10/12 CLA but not by the inactive analog 9/11 CLA (n ϭ 5, P ϭ 0.01 for TO-901317 vs. DMSO, P ϭ 0.004 for TO-901317 vs. TO-901317 ϩ 10/12 CLA, P ϭ 0.04 for TO-901317 ϩ 10/12 CLA vs. TO-901317 ϩ 9/11 CLA, P ϭ 0.91 for TO-901317 vs. TO-901317 ϩ 9/11 CLA). B: changes in product precursor ratios of SCD-1 are shown to estimate the effect of treatments with TO-901317 and CLA on SCD-1 activity in HAECs under conditions analogous to A. The SCD-1 activity index for C16:1/C16:0, C18:1/C18:0, and the sum of both (C16:1ϩC18:1)/(C16: 0ϩC18:0) after a 20-h treatment with TO-901317, 10/12 CLA, and 9/11 CLA is displayed. The increase of all 3 indexes by TO-901317 is reduced to basal levels by the SCD-1 inhibitor 10/12 CLA. The inactive analog 9/11 CLA shows no significant reduction of TO-901317-induced elevation of SCD-1 indexes. The values for C18:1/C18:0 and the combined (C16:1 ϩ C18:1)/C16:0ϩC18:0 index remain significantly higher than basal (n ϭ 3). C: palmitate also induces apoptosis in HAECs. HAECs were treated with 0.6 mM palmitate for 36 h. Apoptosis was determined as the subG1 fraction in a cell cycle assay (n ϭ 5, p ϭ 0.001). D: inhibition of hSCD-1 activity by 10/12 CLA reverses the protective effects of TO-901317 against palmitate-induced endothelial cell apoptosis. Apoptosis was determined as the subG1 fraction in a cell cycle assay. Data are expressed as a relative change of apoptosis in TO-901317-treated vs. untreated cells (n ϭ 5, P ϭ 0.002). Addition of 10/12 CLA, an inhibitor of hSCD-1 activity, completely reverses the protective effects of TO-901317 (n ϭ 5, P Ͻ 0.5). *P Ͻ 0.05, different from control; **P Ͻ 0.01, different from control; #P Ͻ 0.05, different from TO-901317 treatment; ##P Ͻ 0.01, different from TO-901317 treatment; §P Ͻ 0.05, different from TO-901317 ϩ 10/12 CLA treatment; § §P Ͻ 0.01, different from TO901317 ϩ 10/12 CLA treatment. NS, not significant. knockdown of hSCD-1 (Fig. 6B) . These results together with the results shown in Fig. 5 provide molecular and pharmacological evidence that the induction of hSCD-1 expression and hSCD-1 enzyme activity is necessary for the protective effects of the LXR activator TO-901317 against lipotoxicity.
SCD-1 knockdown prevents reduction of palmitate-induced cytotoxicity by
The LXR activator TO-901317 prevents palmitate-induced expression of inflammatory cytokines IL-6 and IL-8 in HAECs.
An important aspect of lipotoxicity in endothelial cells is the induction of inflammatory cytokines and triggering of local inflammation in the vessel wall. Exposure to palmitate (0.5 mM for 20 h) led to a strong induction of IL-6 mRNA expression (29.2 Ϯ 7.0-fold, P ϭ 0.02) (Fig. 7A) . In previous studies, these experimental conditions also increased IL-6 protein production (44) . Of note, no apoptosis under this shorter exposure to palmitate was observed other than that used for cytotoxicity assays (20 h 0.5 mM) (44) . Preincubation with 10 M TO-901317 significantly reduced this IL-6 induction by 63% (10.8 Ϯ 1.8-fold, P ϭ 0.01). Similarly, the expression of IL-8 was induced by palmitate (15.2 Ϯ 4.3-fold, P ϭ 0.05), with a significant reduction after pretreatment with 10 M TO-901317 by 60% (6.3 Ϯ 1.0-fold, P Ͻ 0.01) (Fig. 7B) . Addition of the SCD-1 inhibitor 10/12 CLA attenuated the protective effect of TO-901317 on IL-6 expression (P ϭ 0.03) and abolished the effect on IL-8 induction (P Ͻ 0.01), whereas the effect of palmitate alone remained largely unaltered (Fig. 7,   A and B) . These results indicate that reduction of palmitateinduced cytokine expression by TO-901317 is dependent on induction of SCD-1.
Induction of hSCD-1 facilitates lipid accumulation in saturated NEFA-exposed HAECs.. To demonstrate that the induction of hSCD-1 by TO-901317 leads to enhanced storage of exogenous saturated fatty acids in triglycerides, we performed lipid staining in endothelial cells. In the absence of free fatty acids, HAECs did not contain any lipid droplets detectable in an Oil Red O staining. Upon treatment with unsaturated NEFAs like 0.6 mM oleate for 2 h, a massive accumulation of small perinuclear lipid droplets became visible (Fig. 8A) . Using palmitate or stearate, no lipid accumulation in HAECs was found. After preincubation with the LXR activator TO-901317 (10 M for 20 h), formation of lipid droplets became visible upon palmitate and stearate exposure, comparable with cells exposed to oleate. To confirm these observations, triglycerides were measured in whole cell lysates of endothelial cells incubated for 5 h with palmitate or oleate (Fig. 8B) . Oleate led to a significant increase in triglyceride content. Palmitate was stored only as triglycerides after preincubation with TO-901317, but not under basal conditions. Together, the results show a rapid and unexpected lipid accumulation in HAECs after exposure to NEFA but only when unsaturated NEFAs are provided either extracellularly or by SCD-1-mediated desaturation of NEFAs.
DISCUSSION
Disadvantageous effects of saturated fatty acids on endothelial function are well described in vivo and in vitro. Although saturated fatty acids palmitate and stearate cannot be stored and induce apoptosis in primary human arterial endothelial cells, unsaturated fatty acids like oleate or palmitoleate are not toxic and can be stored as triglycerides (30) . Since the pathobiochemistry underlying the particularly deleterious effects of saturated fatty acids in the vasculature are unclear, we set out to elucidate the molecular mechanism and preventive strategies in primary HAECs.
The major findings of our studies are that 1) HAECs express hSCD-1 protein, 2) the expression of hSCD-1 is not enhanced by palmitate treatment, whereas palmitate induces hSCD-1 expression in human myotubes, HepG2, and human coronary artery smooth muscle cells, 3) overexpression of hSCD-1 attenuates palmitate-induced toxicity, 4) the LXR activator TO-901317 induces hSCD-1 expression and activity in HAECs and reduces palmitate-induced cytotoxicity, apoptosis, and inflammatory cytokine expression, 5) these effects can be attributed to hSCD-1 activity since inhibition with 10/12 CLA, but not with the inactive 9/11 CLA, attenuates the benign TO-901317 effects, 6) TO-901317 does not protect from lipotoxicity in an SCD-1 knockdown model, and 7) HAECs may rapidly (2-5 h) accumulate triglycerides upon treatment with oleate; saturated NEFAs led only to lipid accumulation when cells were preincubated with TO-901317. Vascular endothelial cells display remarkable heterogeneity between species and even between vein and arteries of different vascular beds (2, 5, 28, 39) . Because atherosclerotic lesions predominantly occur in large vessels first, we used large vessel-derived (1) primary human arterial endothelial cells from healthy individuals (3) throughout our studies to stay as close to the human situation as possible. Due to a limited transfection capacity of primary human cells, we used HEK-293 cells for some molecular studies. The NEFA concentrations used in the experiments are also within the range that is reached in the plasma of healthy human subjects (44) . Our results suggest that the lipotoxic effects of saturated fatty acids on HAECs are caused by their inability to respond to this challenge by inducing the expression of hSCD-1 with subsequent conversion of the saturated to monounsaturated fatty acids, which in turn, together with saturated fatty acids, can be incorporated into neutral lipids. In Chinese hamster ovary cells, unsaturated fatty acids, either by exogenous addition or by endogenous desaturation through overexpression of SCD-1, rescue palmitate-induced apoptosis by channeling palmitate into triglyceride pools away from pathways leading to apoptosis (30) . In the murine pancreatic ␤-cell line MIN6, the selection of a palmitate-resistant subpopulation that is characterized by increased SCD-1 expression and inducibility by palmitate was reported (7) . Supporting these data, loss of SCD-1 worsens diabetes in leptin-deficient obese mice through accelerated ␤-cell failure (16) . SCD-1 appears to be necessary for triglyceride storage, as knockout mouse models strike by a lack of hepatic triglycerides and prevention of hepatic steatosis in ob/ob mice (10) . Therefore, we conclude that the LXR activator TO-901317 protects against palmitate-induced lipotoxicity by increased hSCD-1-mediated desaturation of palmitate to palmitoleate and incorporation into triglycerides. Accumulation of triglycerides in nonadipose tissues appears to be a measure of the lipid-overload state associated with insulin resistance, hyperlipidemia, and obesity. Our experiments, similarly to results obtained in Chinese hamster ovary and pancreatic ␤-cells, indicate that cellular lipid accumulation itself is not initially toxic (7, 30) . Rather, deposition of excess NEFA in lipid depots withdraws these metabolites from pathways to exerting their deleterious effects. Rapid storage in neutral lipids can be a mechanism of protecting the cells from postprandially occurring peak levels of circulating NEFAs. However, in chronic states of increased NEFAs when cellular capacity of lipid storage is exceeded, intracellular NEFA levels may increase and exert toxic effects. Together, these are several arguments for why SCD-1 expression is crucial to the prevention of lipotoxicity induced by saturated NEFAs.
The LXR activators like TO-901317 have proven antiatherogenic properties in mouse models (27, 50) . The effect has been attributed mainly to an influence on reverse cholesterol transport and inhibition of NF-B activation in macrophages (19, 27, 57) . We have recently demonstrated NF-B-dependent induction of apoptosis by palmitate in endothelial cells (45) . Our data show that the LXR activator TO-901317 additionally prevents initial steps of palmitate-induced lipotoxicity through induction of hSCD-1 since the observed protective effects were inhibited by SCD-1 knockdown or the SCD-1 inhibitor 10/12 CLA. The present study provides evidence that protection of the LXR activator TO-901317 against atherosclerosis can be, at least in part, due to reduced NEFA-induced endothelial cell apoptosis and inflammation. While this article was in preparation, laminar shear stress-induced expression of SCD-1 in vascular endothelial cells was reported, adding further importance to our findings (36) . Those authors postulated a contribution of endothelial SCD-1 expression to the antiatherosclerotic effects of laminar flow in straight vessels. Pharmacological prevention of lipotoxicity in endothelial cells represents a valuable tool for vascular protection reaching from initiation of endothelial dysfunction to vascular complications, myocardial infarction, and stroke. This adds a novel aspect to the protective mechanisms of LXR-activating drugs in vascular disease. Activation of hepatic SREBP-1c target genes and consecutive hepatic steatosis, as well as unfavorable plasma lipid profile with elevated plasma triglycerides, are seen as serious side effects of LXR activators as therapeutic agents that could limit their applicability (19) . On the other hand, inhibition of hepatic SCD-1 activity is currently discussed as potential treatment for obesity, insulin resistance, and the metabolic syndrome (10, 14, 17, 21 ). An unselective inhibition of SCD-1 that includes vascular endothelial cells is likely to increase lipotoxicity in these cells, thus augmenting atherosclerosis. Thus, this study stresses the potential opposing disease-related effects of SCD-1 in different tissues and demonstrates the need for tissue-specific acting drugs.
